AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression
Alexandra Borodovsky, et al. Cancer Research 2017 July;Volume 77, Issue 13 .
|Related Adenosine Receptor Products|
CPI-444 is a potent and selective inhibitor of A2A receptor (A2AR) induces antitumor responses.
Regadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing.
ZM-241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
Pentostatin (Deoxycoformycin) is an irreversible inhibitor of adenosine deaminase (Ki = 2.5 pM).
CGS 21680 is a selective adenosine receptor agonist for A2A and A3 with Ki of 15 ng/mL and 37 ng/mL, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.